EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Targeting WEE1 Kinase for Breast Cancer Therapeutics: An Update

Zhao Zhang, Ritika Harish, Naveed Elahi, Sawanjit Saini, Aamir Telia, Manjit Kundlas, Allexes Koroleva, Israel N Umoh, Manpreet Lota, Meha Bilkhu, Aladdin Kawaiah, Manogna R Allala und 6 weitere

International Journal of Molecular Sciences · 13.06.2025 · 26 (12) · 5701

DOI: 10.3390/ijms26125701 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 13.06.2025. Verfasst von Zhao Zhang und 17 weiteren Autor:innen. Beteiligte Einrichtung: Pennsylvania Cancer and Regenerative Medicine Research Center, Baruch S. Blumberg Institute, 100 East Lancaster Avenue, LIMR R234, Wynnewood, PA 1909…. Hauptthemen laut MEDLINE: Protein-Tyrosine Kinases, Cell Cycle Proteins, Breast Neoplasms, Protein Kinase Inhibitors. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 159 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Research, Development and Innovation Fund of the Ministry of Culture and Innovation (Hungary), DOD Breakthrough Breast Cancer Research Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

WEE1 kinase is a crucial cell cycle regulatory protein that controls the timing of mitotic entry. WEE1, via inhibition of Cyclin-dependent Kinase 1 (CDK1) and Cyclin-dependent Kinase 2 (CDK2), governs the G2-M checkpoint by inhibiting entry into mitosis. The state of balance between WEE family kinases and CDC25C phosphatases restricts CDK1/CycB activity. The WEE kinase family consists of WEE1, PKMYT1, and WEE2 (WEE1B). WEE1 and PKMYT1 regulate entry into mitosis during cell cycle progression, whereas WEE2 governs cell cycle progression during meiosis. Recent studies have identified WEE1 as a potential therapeutic target in several cancers, including therapy-resistant triple-negative breast cancer. Adavosertib’s clinical promise was challenged by inter-individual variations in response and side effects. Because of these promising preclinical outcomes, other WEE1 kinase inhibitors (Azenosertib, SC0191, IMP7068, PD0407824, PD0166285, WEE1-IN-5, Zedoresertib, WEE1-IN-8, and ATRN-1051) are being developed, with several currently being evaluated in clinical trials or as an adjuvant to chemotherapies. Preclinical studies show WEE1 inhibitors induce MHC class 1 antigens and STING when given as combination therapies, suggesting potential additional therapeutic opportunities. Reliable predictors of clinical responses based on mechanistic insights remain an important unmet need. Herein, we review the role of WEE1 inhibition therapy in breast cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Protein-Tyrosine KinasesCell Cycle ProteinsBreast NeoplasmsProtein Kinase InhibitorsAntineoplastic AgentsHumansFemaleAnimalsMolecular Targeted TherapyPyrazolesPyrimidinones

Stichwörter der Autor:innen

DNA damage/repairG2/M checkpointWEE1 inhibitorsWEE1 kinasebreast cancercell cycle regulationchemotherapy resistanceclinical trialcyclin-dependent kinasesmitotic entry

Substanzen

Protein-Tyrosine KinasesWEE1 protein, humanCell Cycle ProteinsProtein Kinase InhibitorsAntineoplastic AgentsadavosertibPyrazolesPyrimidinones

Autor:innen und Institutionen

  • Pennsylvania Cancer and Regenerative Medicine Research Center, Baruch S. Blumberg Institute, 100 East Lancaster Avenue, LIMR R234, Wynnewood, PA 19096, USA.
  • Xavier University School of Medicine at Aruba, Woodbury, NY 11797, USA.
  • Lankenau Institute for Medical Research, Wynnewood, PA 19096, USA.
  • HUN-REN Office for Supported Research Groups, Cell Cycle Laboratory, National Institute of Oncology, 1122 Budapest, Hungary.
  • Chemistry Coordinating Institute, University of Debrecen, 4012 Debrecen, Hungary.
  • Semmelweis University, 1117 Budapest, Hungary.

ORCID-Profile: Anthony W Ashton, Richard G Pestell

Förderung

  • NCI NIH HHS
  • National Research, Development and Innovation Fund of the Ministry of Culture and Innovation (Hungary)
  • DOD Breakthrough Breast Cancer Research Program
  • NIH HHS
  • NIH
  • DOD Breakthrough Breast Cancer Research Program grant award
  • National Research, Development and Innovation Office, Hungary

Zitieren

APA

Zhang, Z., Harish, R., Elahi, N., Saini, S., Telia, A., Kundlas, M., Koroleva, A., Umoh, I. N., Lota, M., Bilkhu, M., Kawaiah, A., Allala, M. R., Leukeu, A., Nebuwa, E., Sharifi, N., Ashton, A. W., Jiao, X., & Pestell, R. G. (2025). Targeting WEE1 Kinase for Breast Cancer Therapeutics: An Update. International Journal of Molecular Sciences, 26(12), 5701. https://doi.org/10.3390/ijms26125701

Vancouver

Zhang Z, Harish R, Elahi N, Saini S, Telia A, Kundlas M, et al. Targeting WEE1 Kinase for Breast Cancer Therapeutics: An Update. International Journal of Molecular Sciences. 2025;26(12):5701. doi:10.3390/ijms26125701

BibTeX
@article{Zhang2025,
  author = {Zhang, Zhao and Harish, Ritika and Elahi, Naveed and Saini, Sawanjit and Telia, Aamir and Kundlas, Manjit and Koroleva, Allexes and Umoh, Israel N and Lota, Manpreet and Bilkhu, Meha and Kawaiah, Aladdin and Allala, Manogna R and Leukeu, Armelle and Nebuwa, Emmanuel and Sharifi, Nadiya and Ashton, Anthony W and Jiao, Xuanmao and Pestell, Richard G},
  title = {Targeting WEE1 Kinase for Breast Cancer Therapeutics: An Update},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  volume = {26},
  number = {12},
  pages = {5701},
  doi = {10.3390/ijms26125701}
}
Kostenlos starten →